Allergan, Serenity Pharmaceuticals Ink Global Agreement For Nocturia

Ser-120 is a new, nasally administered clinical drug candidate in Phase III clinical trials being investigated for its safety and efficacy in relieving the symptoms of nocturia and mitigating excessive urinary frequency at night.

As per the terms of the agreement, Allergan has received exclusive worldwide rights to develop, manufacture and commercialise Ser-120. The agreement encompasses all potential indications except Primary Nocturnal Enuresis (pediatric bedwetting).

Allergan is expected to make an upfront payment to Serenity of $43m, potential development and regulatory milestone payments of up to $122m, future potential sales milestones, and royalty payments on worldwide sales.

Samuel Herschkowitz, CEO of Serenity Pharmaceuticals, said: “There is a significant unmet medical need for the treatment of nocturia, which often affects patients who suffer from urologic conditions such as overactive bladder, benign prostatic hyperplasia and general primary nocturia. With Allergan’s strategic focus on establishing a strong urology franchise and its proven track record in pharmaceutical development and commercialisation, we are convinced that this will be a successful partnership.”

Scott Whitcup, executive vice president, research & development and chief scientific officer at Allergan, said: “We are pleased to be partnering with Serenity to further explore the potential of Ser-120 as a possible treatment for nocturia, a condition that can negatively impact a patient’s quality of life. If successful, Ser-120 would complement our emerging urology portfolio of treatments for a variety of urinary disorders.”